Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

Aldeyra Therapeutics (ALDX)

Aldeyra Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ALDX
DateTimeSourceHeadlineSymbolCompany
20/06/202412:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALDXAldeyra Therapeutics Inc
20/06/202412:00Business WireAldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor RoundtableNASDAQ:ALDXAldeyra Therapeutics Inc
13/06/202412:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALDXAldeyra Therapeutics Inc
13/06/202412:00Business WireAldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye DiseaseNASDAQ:ALDXAldeyra Therapeutics Inc
12/06/202412:00Business WireAldeyra Therapeutics to Host Investor Roundtable Q&ANASDAQ:ALDXAldeyra Therapeutics Inc
07/06/202421:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALDXAldeyra Therapeutics Inc
06/06/202421:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALDXAldeyra Therapeutics Inc
06/06/202421:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALDXAldeyra Therapeutics Inc
06/06/202421:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALDXAldeyra Therapeutics Inc
29/05/202412:00Business WireAldeyra Therapeutics to Participate in the Jefferies Global Healthcare ConferenceNASDAQ:ALDXAldeyra Therapeutics Inc
08/05/202412:00Business WireAldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye DiseaseNASDAQ:ALDXAldeyra Therapeutics Inc
25/04/202412:00Business WireAldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development DayNASDAQ:ALDXAldeyra Therapeutics Inc
18/04/202412:00Business WireAldeyra Therapeutics to Host Research & Development Day on April 25, 2024NASDAQ:ALDXAldeyra Therapeutics Inc
28/03/202411:00Business WireAldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye DiseaseNASDAQ:ALDXAldeyra Therapeutics Inc
07/03/202421:54Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ALDXAldeyra Therapeutics Inc
07/03/202421:48Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ALDXAldeyra Therapeutics Inc
07/03/202421:40Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:ALDXAldeyra Therapeutics Inc
07/03/202421:06Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ALDXAldeyra Therapeutics Inc
06/02/202412:00Business WireAldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:ALDXAldeyra Therapeutics Inc
29/01/202422:25Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ALDXAldeyra Therapeutics Inc
04/01/202412:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALDXAldeyra Therapeutics Inc
04/01/202412:00Business WireAldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory DiseasesNASDAQ:ALDXAldeyra Therapeutics Inc
21/12/202321:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALDXAldeyra Therapeutics Inc
19/12/202312:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALDXAldeyra Therapeutics Inc
19/12/202312:00Business WireAldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX‑629 in Patients with Atopic DermatitisNASDAQ:ALDXAldeyra Therapeutics Inc
18/12/202321:01Business WireAldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Phase 2 Clinical Trial of ADX-629 in Patients with Atopic DermatitisNASDAQ:ALDXAldeyra Therapeutics Inc
28/11/202312:16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALDXAldeyra Therapeutics Inc
27/11/202321:07Business WireAldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye DiseaseNASDAQ:ALDXAldeyra Therapeutics Inc
03/11/202320:43Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ALDXAldeyra Therapeutics Inc
03/11/202320:08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALDXAldeyra Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ALDX